University of Utah Research Foundation

Janssen Pharmaceutica Nv

Neuroadjuvants, Inc

H Steve White

Yong Moon Choi

Boyu Zhao

Roy E Twyman

Grzegorz Bulaj

Brian D Klein

Louis Ptacek

Ying-Hui Fu

Liuyin Zhang

Daniel Ryan McDougle

Erika Adkins Scholl

Shana Skradski

Cameron Spencer Metcalf

Misty Danielle Smith

Gerald P Novak

Daniel Ryan Mcdougle

Robert Gordon

Brian Donald Klein

Carlos R Plata-Salaman

Neuropeptide analogs and compositions including neuropeptide analogs are described herein. Also provided are methods of producing and using the neuropeptide analogs and compositions including one or more neuropeptide analogs.

Neuropeptide analogs, compositions, and methods for treating pain

Disclosed are compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system.

Methods and compositions related to improving properties of pharmacological agents targeting nervous system

The present invention relates to a novel gene which is associated with audiogenic seizures in mice. The gene is known as the Monogenic Audiogenic Seizure-susceptible gene or mass1. The product of the mass1 gene is designated MASS1. Nucleic acid molecules that encode for MASS1 have been identified and purified. The sequence of murine mass1 can be found at SEQ ID NO: 1, and the sequence of human mass1 can be found at SEQ ID NO: 3. Mammalian genes encoding a MASS1 protein are also provided. The invention also provides recombinant vectors comprising nucleic acid molecules that code for a MASS1 protein. These vectors can be plasmids. In certain embodiments, the vectors are prokaryotic or eukaryotic expression vectors. The nucleic acid coding for MASS1 can be linked to a heterologous promoter. The invention also relates to transgenic animals in which one or both alleles of the endogenous mass1 gene is mutated.

Mass1 gene, a target for anticonvulsant drug development

Growing community of inventors

Salt Lake City, UT, United States of America

H Steve White